160 related articles for article (PubMed ID: 29359145)
21. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
22. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
Nagill R; Mahajan R; Sharma M; Kaur S
Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
[TBL] [Abstract][Full Text] [Related]
23. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
25. Immunological responses induced by a DNA vaccine expressing RON4 and by immunogenic recombinant protein RON4 failed to protect mice against chronic toxoplasmosis.
Rashid I; Hedhli D; Moiré N; Pierre J; Debierre-Grockiego F; Dimier-Poisson I; Mévélec MN
Vaccine; 2011 Nov; 29(48):8838-46. PubMed ID: 21983362
[TBL] [Abstract][Full Text] [Related]
26. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
[TBL] [Abstract][Full Text] [Related]
27. Leishmaniasis: current status of vaccine development.
Sukumaran B; Madhubala R
Curr Mol Med; 2004 Sep; 4(6):667-79. PubMed ID: 15357215
[TBL] [Abstract][Full Text] [Related]
28. Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis.
Cui X; Lei T; Yang D; Hao P; Li B; Liu Q
Vaccine; 2012 Mar; 30(13):2282-7. PubMed ID: 22310204
[TBL] [Abstract][Full Text] [Related]
29. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
[TBL] [Abstract][Full Text] [Related]
31. Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice.
Amit A; Vijayamahantesh ; Dikhit MR; Singh AK; Kumar V; Suman SS; Singh A; Kumar A; Thakur AK; Das VR; Das P; Bimal S
Mol Immunol; 2017 Feb; 82():104-113. PubMed ID: 28064069
[TBL] [Abstract][Full Text] [Related]
32. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
34. Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.
Fiuza JA; Dey R; Davenport D; Abdeladhim M; Meneses C; Oliveira F; Kamhawi S; Valenzuela JG; Gannavaram S; Nakhasi HL
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004322. PubMed ID: 26752686
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
Henriquez FL; Campbell SA; Roberts CW; Mullen AB; Burchmore R; Carter KC
J Parasitol; 2010 Oct; 96(5):929-36. PubMed ID: 20950100
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis.
Masih S; Arora SK; Vasishta RK
Exp Parasitol; 2011 Sep; 129(1):55-64. PubMed ID: 21640106
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
38. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
Mukherjee M; Bhattacharyya A; Duttagupta S
Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
[TBL] [Abstract][Full Text] [Related]
39. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.
Badiee A; Jaafari MR; Samiei A; Soroush D; Khamesipour A
Clin Vaccine Immunol; 2008 Apr; 15(4):668-74. PubMed ID: 18235040
[TBL] [Abstract][Full Text] [Related]
40. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
Bhowmick S; Mazumdar T; Sinha R; Ali N
J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
